These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8071039)

  • 41. Inhibition of acetylcholinesterase by some organic contrast media. A preliminary communication.
    Lasser EC; Lang JH
    Invest Radiol; 1966; 1(3):237-42. PubMed ID: 5938802
    [No Abstract]   [Full Text] [Related]  

  • 42. Tolerance and biochemical pharmacology of iopromide.
    Mützel W; Speck U
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():11-7. PubMed ID: 6195966
    [No Abstract]   [Full Text] [Related]  

  • 43. [Preclinical assay on a magnetic carrier type ferrofluid].
    Bredeţean O; Ciochină AD; Iacob G; Dimitriu CD; Teleman S; Popa PD
    Rev Med Chir Soc Med Nat Iasi; 2002; 106(4):796-800. PubMed ID: 14974232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preparation, characterization, and evaluation of ioxilan carbonate particles for computed tomography contrast enhancement of liver.
    Li C; Kan Z; Yang DJ; Kuang LR; Liu CW; Wright KC; Wallace S
    Invest Radiol; 1994 Nov; 29(11):1006-13. PubMed ID: 7890508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gd(ABE-DTTA), a novel contrast agent, at the MRI-effective dose shows absence of deleterious physiological effects in dogs.
    Ruzsics B; Surányi P; Kiss P; Brott BC; Elgavish A; Saab-Ismail NH; Simor T; Elgavish GA
    Pharmacology; 2006; 77(4):188-94. PubMed ID: 16877874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of roentgen contrast media on the mast cells of albino rats].
    Sergeev PV; Prosvirnina ON; Takhtarova NB; Chistiakov VA
    Farmakol Toksikol; 1967; 30(6):747-9. PubMed ID: 5598451
    [No Abstract]   [Full Text] [Related]  

  • 47. New magnetic resonance imaging contrast agents for infarct imaging based on phosphonate derivatives of Gd-DTPA.
    Adzamli IK; Blau M; Pfeffer MA; Davis MA
    Invest Radiol; 1991 Nov; 26 Suppl 1():S242-4; discussion S245-7. PubMed ID: 1808139
    [No Abstract]   [Full Text] [Related]  

  • 48. [Evaluation of manganese-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging].
    Usov VIu; Balianin ML; Bezlepkin AI; Churin AA; Dubskaia TIu; Vetoshkina TL; Filimonov VD
    Eksp Klin Farmakol; 2013; 76(10):32-8. PubMed ID: 24400387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Iohexol. A non-ionic contrast medium. Pharmacology and toxicology.
    Acta Radiol Suppl; 1980; 362():1-134. PubMed ID: 6267880
    [No Abstract]   [Full Text] [Related]  

  • 50. [Which investigations can be conducted by the industry before the introduction of a new contrast medium?].
    Herms HJ
    Radiol Diagn (Berl); 1967; 8(4):413-9. PubMed ID: 5633466
    [No Abstract]   [Full Text] [Related]  

  • 51. [Hemodynamic effects in man of an injection of a new contrast medium for cholangiography].
    Ambrosioni E; Catizone L; Chiarini C; Costa V; Perri G
    G Clin Med; 1972 Mar; 53(3):132-41. PubMed ID: 4567883
    [No Abstract]   [Full Text] [Related]  

  • 52. Radiopaque contrast media. XXXIV - Derivatives of omega-(3-amino-2,4,6-triiodophenoxy)alkoxyalkanoic acids.
    Felder E; Pitrè D; Fumagalli L; Lorenzotti E
    Farmaco Sci; 1976 May; 31(5):349-63. PubMed ID: 1269739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug evaluation: PB-127, a novel contrast agent for the detection of myocardial perfusion.
    Patrianakos AP; Hamilos MI
    Curr Opin Investig Drugs; 2007 Mar; 8(3):248-55. PubMed ID: 17408121
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Margins of safety of intravascular contrast media: body weight, surface area or toxicokinetic approach?
    Bussi S; Morisetti A
    Arh Hig Rada Toksikol; 2005 Jun; 56(2):157-60. PubMed ID: 15968831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New intravenously applied biliary contrast medium].
    Cassebaum H; Dierbach K; Bekker H
    Pharmazie; 1967 Sep; 22(9):470-4. PubMed ID: 5599141
    [No Abstract]   [Full Text] [Related]  

  • 56. Protective effect of adrenomedullin on contrast induced nephropathy in rats.
    Inal S; Koc E; Ulusal-Okyay G; Pasaoglu OT; Isik-Gönül I; Oz-Oyar E; Pasaoglu H; Güz G
    Nefrologia; 2014 Nov; 34(6):724-31. PubMed ID: 25335086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concepts in design of improved intravascular contrast agents.
    Sovak M; Ranganathan R; Lang JH; Lasser EC
    Ann Radiol (Paris); 1978; 21(4-5):283-9. PubMed ID: 718082
    [No Abstract]   [Full Text] [Related]  

  • 58. Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection.
    Van Wagoner M; O'Toole M; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S39-41. PubMed ID: 2283251
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effects of new angiographic contrast media on the cardio-respiratory- and central nervous system].
    sebök ZB; Szlávy L
    Arzneimittelforschung; 1967 Nov; 17(11):1380-6. PubMed ID: 5632272
    [No Abstract]   [Full Text] [Related]  

  • 60. Ioxilan. Initial clinical observations.
    Callantine MR; Sovak M; Lu HP
    Invest Radiol; 1990 Sep; 25 Suppl 1():S107-8. PubMed ID: 2283219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.